Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15649843 | 0.81 | CYP1A2 (0.49) | TDP1TSHRGAAMAPK1ALDH1A1 | |
| SCHEMBL20101952 | 0.80 | ALDH1A1 (0.40) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL4247977 | 0.79 | ABL1 (0.40) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL13731286 | 0.79 | DAPK3 (0.40) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL11286998 | 0.78 | KDM4E (0.46) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| Hydrochloric Acid SCHEMBL1396143 | 0.78 | ABL1 (0.39) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL4051027 | 0.78 | MEN1 (0.35) | TDP1TSHRKDM4EHSD17B10MAPT | |
| Ethane SCHEMBL15559374 | 0.77 | ABL1 (0.38) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL5048134 | 0.75 | ALDH1A1 (0.42) | DAPK3JAK2PRKD3MAP4K4ABL1 | |
| SCHEMBL31294085 | 0.75 | NOTUM (0.43) | DAPK3JAK2PRKD3MAP4K4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY THERAPEUTICS, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| CN-119365460-A | Compounds that interact with Ras superfamily proteins for the treatment of cancer, inflammatory diseases, RAS diseases, and fibrotic diseases | 尚医治疗有限责任公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240360141-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2024-10-31 | — | — | US | disclosed |
| US-11827642-B2 | Compositions useful for treating disorders related to KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023196975-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230129944-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-10807985-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190144454-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2019-05-16 | — | — | US | disclosed |
| EP-3202767-B1 | AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2019-04-03 | — | — | EP | disclosed |
| US-20170296537-A1 | AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEROF AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2017-10-19 | — | — | US | disclosed |
| US-20170296537-A1 | AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEROF AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2017-10-19 | — | — | US | disclosed |
| EP-3202767-A1 | AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2017-08-09 | — | — | EP | disclosed |
| WO-2014124757-A1 | PYRROLOTRIAZINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2014-08-21 | — | — | WO | disclosed |
| EP-1446401-B1 | C5-modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-1446401-A4 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL MYERS SQUIBB CO (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050209235-A1 | C-5 Modified indazolylpyrrolotriazines | MASTALERZ HAROLD | 2005-09-22 | — | — | US | disclosed |
| US-6908916-B2 | C-5 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1446401-A2 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | Bristol-Myers Squibb Company (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030186983-A1 | C-5 Modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-02 | — | — | US | disclosed |
| WO-2003042172-A2 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807985-B2 | Compositions useful for treating disorders related to kit | KIT, APC, MSH2 | DAPK3 3834/4885JAK2 2552/4885PRKD3 156/4885 |
| US-20030186983-A1 | C-5 Modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | DAPK3 750/4885JAK2 51/4885PRKD3 729/4885 |
| US-20190144454-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, MSH2 | DAPK3 3834/4885JAK2 2552/4885PRKD3 156/4885 |
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | KRAS, HRAS, NRAS | DAPK3 2128/4885JAK2 1824/4885PRKD3 1874/4885 |
| US-20050209235-A1 | C-5 Modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | DAPK3 649/4885JAK2 53/4885PRKD3 741/4885 |
| US-20240360141-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, HRAS, NRAS | DAPK3 2128/4885JAK2 1824/4885PRKD3 1874/4885 |
| US-11827642-B2 | Compositions useful for treating disorders related to KIT | KIT, APC, MSH2 | DAPK3 3834/4885JAK2 2552/4885PRKD3 156/4885 |
| US-20170296537-A1 | AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEROF AND MEDICAL USE THEREOF | EGFR, ERBB2, ERBB4 | DAPK3 1210/4885JAK2 439/4885PRKD3 3196/4885 |
| US-20230129944-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, MSH2 | DAPK3 3834/4885JAK2 2552/4885PRKD3 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.